Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer

Published:2024-01-22 Issue:3 Volume:40 Page:441-453
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Qi Huijie¹,Zhang Wenxin¹,Chen Bicui¹,Zhan Qiong²,Wang Tianxiao¹,Shi Huanying¹,Liu Yanchen³,Wang Yan¹,Zhong Mingkang¹,Shi Xiaojin¹,Shen Fangfang⁴,Li Qunyi¹

Affiliation:

1. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China

2. Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China

3. Audit Specialty, Accounting Institute, Shanghai Lixin University of Accounting and Finance, Shanghai, China

4. Public Relations Department, Huashan Hospital, Fudan University, Shanghai, China

Funder

National Natural Science Foundation of China

Scientific Research Project of Shanghai Health and Family Planning Commission

Shanghai Sailing Program

Shanghai ‘Rising Stars of Medical Talent’ Youth Development Program

Shanghai Key Clinical Specialty Projects-Clinical Pharmacy

Clinical pharmacy management committee of Shanghai Hospital Association